Scientific Programme
Scientific
Programme
November 6, 2025 -Thursday |
|
|---|---|
Eğitim – Klinik Araştırmalarda Risk Değerlendirmesi ve Biyobenzer Ürünlerde İmmünojenisite Testleri |
|
Risk Değerlendirmesine İlişkin Rapor Hazırlanmasında Dikkat Edilecek Husular |
|
| 13.00-13.30 | Faz I klinik çalışmalarını desteklemek için kullanılan klinik öncesi verilerin risk değerlendirmesi Prof. Dr. Yalçın Duydu |
| 13.30-14.00 | Klinik araştırmalarda risk değerlendirme raporunda dikkat edilecek hususlar Dr. Ecz. Hilal İlbars |
| 14.00-14.30 | Sağlık otoritesi açısından klinik araştırmalarda risk değerlendirmesinde önemli hususlar Daha sonra duyurulacak |
| 14.30-15.00 | İlaç sektörü açısından klinik araştırmalarda risk değerlendirmesinde karşılaşılan sorunlar Daha sonra duyurulacak |
| 15.00-15.30 | Kahve arası |
Biyobenzer Ürünlerde İmmunogenisite Testlerinin Önemi |
|
| 15.30-16.00 | Biyobenzer ürünlerde immünojenisite testleri Prof. Dr. Bensu Karahalil |
| 16.00-16.30 | Biyobenzer ürün geliştirilmesinde immünojenisite testlerinin önemi Daha sonra duyurulacak |
| 16.30-17.00 | Biyobenzer ürünlerde ülkemizdeki durum Daha sonra duyurulacak (TİTCK) |
| 17.00-17.30 | Biyobenzer ürünlerde karşılaşılan sorunlar Daha sonra duyurulacak |
| 18.00-18.20 | Welcome |
| 18.20-18.50 | Opening Lecture One health in the perspective of a toxicologist Félix Carvalho (Portugal) |
| 19.00-21.00 | Opening Reception |
November 7, 2025 -Friday |
|
| 09.00-09.30 | Plenary Lecture Toxicological consideration and risk assessment of drug impurities Biljana Antoijevic (Serbia) |
SESSION 1: Advances in Food Safety and Risk Assessment: Emerging Challenges and Solutions |
|
| 09.30-10.00 | Toxic metals in food and their emerging role as risk factors in hormone-related reproductive cancers Aleksandra Buha (Serbia) |
| 10.00-10.30 | Food safety risk assessment in Türkiye Serap Hancı (Türkiye) |
| 10.30-11.00 | Challenges of the risk assessment of dietary microplastics María-Carmen Rubio-Armendáriz (Canary Islands, Spain) |
| 11.00-11.15 | Coffee break |
SESSION 2: Epigenetic Mechanisms in Toxicology |
|
| 11.15-11.45 | Epigenetic biomarkers for chemical hazard assessment Joëlle Rüegg (Sweden) |
| 11.45-12.15 | AHR-mediated m6A RNA methylation contributes to PM2.5-induced cardiac defects Tao Chen (China) |
| 12.15-12.45 | Role of epigenetic modifications in the toxicity mechanisms of Fusarium-induced mycotoxins Ecem Fatma Karaman (Türkiye) |
| 12.45-14.00 | Lunch Break |
Industry Sponsored Workshop*
MatTek (click here for workshop brochure) |
|
| 14.00-16.00 | *The number of participants for the MatTek Workshop is limited to 40. Therefore, those who wish to participate in this workshop must register their names with the Congress Secretary, Prof. Dr. Özlem ATLI EKLİOĞLU (e-mail: ecz.oatli@gmail.com). For more information about the workshop; MatTek. |
SESSION 3: New Approaches to In Vitro Efficacy/Toxicity Assessment – Advantages and Limitations |
|
| 14.00-14.30 | New air-liquid interface (ALI) system approach for drug efficacy/toxicity testing Merve Güdül Bacanlı (Türkiye) |
| 14.30-15.00 | Challenges in implementing new approaches methodologies in the risk assessment of nanomaterials Ivana Vinković Vrček (Croatia) |
| 15.00-15.30 | Organoid models to test drug safety and efficacy Esra Erdal (Türkiye) |
| 15.30-16.00 | Advancements of in vitro methods for inhalation toxicity towards next generation risk assessment Tommaso Serchi (Luxembourg) |
SESSION 4: Transporters in Toxicology – Unraveling Mechanisms of Xenobiotic Exposure, Metabolic Dysfunction, and Reproductive Health |
|
| 16.00-16.30 | Fetoplacental toxicity and mycoestrogens at the placental barrier Lauren M. Aleksunes (USA) |
| 16.30-17.00 | Multidrug resistance protein 4 dysfunction drives hepatic steatosis and metabolic dysregulation: Integrated in vivo and in vitro insights José E. Manautou (USA) |
| 17.00-17.30 | Integrating drug development tools to predict per- and polyfluoroalkyl (PFAS)-transporter interactions and disposition to human liver Angela L. Slitt (USA) |
| 17.30-17.45 | Coffee Break |
SESSION 5: Safety in Psychotropic Medications Treatment |
|
| 17.45-18.15 | Monitoring the safety and tolerability of antipsychotic drug treatment Christoph Hiemke (Germany) |
| 18.15-18.45 | Comprehensive overview on intoxications with psychotropic drugs Fredrik C. Kugelberg (Sweden) |
| 18.45-19.15 | Pharmacokinetic genes variations and response to treatment: the examples of risperidone, aripiprazole and clozapine Eap-Bin Chin (Switzerland) |
| 19.15-19.45 | The impact of pharmacodynamic gene variations on adverse drug reactions in antidepressant treatment Sinan Süzen (Türkiye) |
November 8, 2025 -Saturday |
|
| 09.00-09.30 | Plenary Lecture Toxicology risk management through interdisciplinary approaches to meet ESG requirements and sustainability challenges Salmaan Hussain B Inayat Hussain (Malaysia) |
| 09.30-09.45 | Coffee break |
SESSION 6: The Importance of Genotoxicity Tests in the Biomonitoring of Chemical Hazards in Occupational Settings |
|
| 09.45-10.10 | The comet assay in human biomonitoring Andrew Collins (Norway) |
| 10.10-10.35 | Alkaline comet and micronucleus cytome assay – The use of the Methods and Their Perspectives through the results of the HCOMET, HUMNAP, EDIAQI, AND BIOMOLTOX Projects Mirta Milic (Croatia) |
| 10.35-11.00 | Steel industry in Bosnia and Herzegovina – Human biomonitoring in exposed population Anja Haveric (Bosnia and Herzegovina) |
| 11.00-11.25 | Genotoxicity biomarkers in occupational exposure to hazardous compounds in Portugal: Lessons learned on formaldehyde, antineoplastics and volatile organic compounds Carina Ladeira (Portugal) |
| 11.25-11.50 | Occupational exposure to mineral fibers – biomarkers of exposure, effect and susceptibility Maria Dusinska (Slovakia/Norway) |
| 12.00-13.30 | Lunch break |
SESSION 7: Cutting-edge Advances in NAMs – What’s New and What’s Next
|
|
| 13.30-14.00 | Advancing immunotoxicology: NAMs for immunosuppression and developmental immunotoxicity Emanuela Corsini (Italy) |
| 14.50-14.30 | Advancing ocular safety: insights into the new OECD guideline Helena Kandarova (Slovakia) |
| 14.30-14.45 | NAMs in cosmetics: the future of safety and innovation Zehra Sarıgöl Kılıç (USA) |
| 14.45-15.00 | Computational and predictive analysis in toxicology Sanin Haveric (Bosnia and Herzegovina) |
| 15.00-15.15 | Coffee Break |
SESSION 8: Microplastics – State of the Science and the Impacts on Human Health |
|
| 15.15-15.45 | Understanding microplastics and human health concerns Neslihan Aygun Kocabaş (Belgium) |
| 15.45-16.15 | Challenges of microplastics research in risk assessment: Ensuring generation of quality data Erik Rushton (Netherlands) |
| 16.15-16.45 | Plastic chemical additives: determining human risk from microplastic exposure John Norman (USA) |
| 16.45-17.15 | Microplastics: unfolding consequences Marijana Curcic (Serbia) |
SESSION 9: Advancements in Understanding the Mechanisms of Organ-Specific Toxicity Induced by Chemicals and Drugs |
|
| 17.15-17.45 | New insight into molecular targets and early key events in genotoxicity and renal carcinogenicity of the mycotoxin ochratoxin A Johannes Borchers (Germany) |
| 17.45-18.15 | Towards understanding the mechanism of methanol-induced optic nerve damage by leveraging human data Hilmi Orhan (Türkiye) |
| 18.15-18.45 | Particle-induced acute phase response as a mechanism-of-action of particle-induced cardiovascular disease Ulla Vogel (Denmark) |
| 18.45-19.15 | Human in vitro models for the detection and understanding of chemical-induced nephrotoxicity Paul Jennings (The Netherlands) |
| 20.00 | Gala dinner |
November 9, 2025 -Sunday |
|
| 09.00-09.30 | Plenary Lecture Mode of action-based refined risk assessment for direct and indirect genotoxic carcinogens Andrea Hartwig (Germany) |
SESSION 10: European and National Regulation on Medical Devices – Challenges and Opportunities for Toxicologists |
|
| 09.30-10.00 | Medical devices made of substances: challenges on definitions for classification and biosafety assessment Marco Racchi (Italy) |
| 10.00-10.30 | Toxicological challenges for industry in the application of MDR 745/2017 Nina Eriksen (Denmark) |
| 10.30-11.00 | Methodological aspects for biosafety compliance in medical devices Emanuela Testai (Italy) |
| 11.00-11.30 | Toxicological risk assessment for extractables/leachables in pharmaceuticals and medical devices Ahmet Aydın (Türkiye) |
| 11.30-11.45 | Coffee break |
| 11.45-12.15 | Closing ceremony |
